Ginkgo Biloba for Preventing Cognitive Decline in Older Adults: a Randomized Trial

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2009 Dec 31

PMID 20040554

Citations 124

Authors

Beth E Snitz

Ellen S OMeara

Michelle C Carlson

Alice M Arnold

Diane G Ives

Stephen R Rapp

Judith Saxton

Oscar L Lopez

Leslie O Dunn

Kaycee M Sink

Steven T DeKosky

Affiliations

Soon will be listed here.

Abstract

Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.

Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.

Design, Setting, And Participants: The Ginkgo Evaluation of Memory (GEM) study, a randomized, double-blind, placebo-controlled clinical trial of 3069 community-dwelling participants aged 72 to 96 years, conducted in 6 academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6.1 years.

Intervention: Twice-daily dose of 120-mg extract of G. biloba (n = 1545) or identical-appearing placebo (n = 1524).

Main Outcome Measures: Rates of change over time in the Modified Mini-Mental State Examination (3MSE), in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog), and in neuropsychological domains of memory, attention, visual-spatial construction, language, and executive functions, based on sums of z scores of individual tests.

Results: Annual rates of decline in z scores did not differ between G. biloba and placebo groups in any domains, including memory (0.043; 95% confidence interval [CI], 0.034-0.051 vs 0.041; 95% CI, 0.032-0.050), attention (0.043; 95% CI, 0.037-0.050 vs 0.048; 95% CI, 0.041-0.054), visuospatial abilities (0.107; 95% CI, 0.097-0.117 vs 0.118; 95% CI, 0.108-0.128), language (0.045; 95% CI, 0.037-0.054 vs 0.041; 95% CI, 0.033-0.048), and executive functions (0.092; 95% CI, 0.086-0.099 vs 0.089; 95% CI, 0.082-0.096). For the 3MSE and ADAS-Cog, rates of change varied by baseline cognitive status (mild cognitive impairment), but there were no differences in rates of change between treatment groups (for 3MSE, P = .71; for ADAS-Cog, P = .97). There was no significant effect modification of treatment on rate of decline by age, sex, race, education, APOE*E4 allele, or baseline mild cognitive impairment (P > .05).

Conclusion: Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.

Trial Registration: clinicaltrials.gov Identifier: NCT00010803.

Citing Articles

Improving cognitive impairment through chronic consumption of natural compounds/extracts: a systematic review and meta-analysis of randomized controlled trials.

Hoang L, Lee H, Lee S Front Aging Neurosci. 2025; 16:1531278.

PMID: 39949865 PMC: 11821934. DOI: 10.3389/fnagi.2024.1531278.

Review of Supplements That Patients Commonly Report Using for Dementia.

Frolov A, Wadood A, Kelley B J Clin Med. 2025; 13(24.

PMID: 39768463 PMC: 11727725. DOI: 10.3390/jcm13247541.

Validation of the athletic mental energy scale for Chinese school-age adolescents.

Wu J, Lu F, Wang Y, Kueh Y, Kuan G Sci Rep. 2024; 14(1):18038.

PMID: 39098949 PMC: 11298513. DOI: 10.1038/s41598-024-66931-z.

Co-treatment with the seed of L. and the aerial part of synergistically suppresses Aβ-induced neurotoxicity by altering APP processing.

He M, Kim J, Cho E Food Sci Nutr. 2024; 12(3):1573-1580.

PMID: 38455162 PMC: 10916591. DOI: 10.1002/fsn3.3768.

Knowledge structure and future research trends of body-mind exercise for mild cognitive impairment: a bibliometric analysis.

Zhang J, Yang Z, Fan H Front Neurol. 2024; 15:1351741.

PMID: 38322586 PMC: 10844579. DOI: 10.3389/fneur.2024.1351741.

References

Mohs R . The Alzheimer's Disease Assessment Scale. Int Psychogeriatr. 1996; 8(2):195-203. DOI: 10.1017/s1041610296002578. View

Chen X, Salwinski S, Lee T . Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol. 1997; 24(12):958-9. DOI: 10.1111/j.1440-1681.1997.tb02727.x. View

Wesnes K, Ward T, McGinty A, Petrini O . The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2001; 152(4):353-61. DOI: 10.1007/s002130000533. View

Becker J, Boller F, Saxton J . Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex. 1987; 23(1):59-72. DOI: 10.1016/s0010-9452(87)80019-9. View

van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P . Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol. 2003; 56(4):367-76. DOI: 10.1016/s0895-4356(03)00003-9. View

Hadjiivanova C, Petkov V . Effect of Ginkgo biloba extract on beta-adrenergic receptors in different rat brain regions. Phytother Res. 2002; 16(5):488-90. DOI: 10.1002/ptr.933. View

Kennedy D, Scholey A, Wesnes K . The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000; 151(4):416-23. DOI: 10.1007/s002130000501. View

Lopez O, Becker J, Jagust W, Fitzpatrick A, Carlson M, DeKosky S . Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2005; 77(2):159-65. PMC: 2077558. DOI: 10.1136/jnnp.2004.045567. View

Teng E, Chui H . The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987; 48(8):314-8. View

10.

Rapp S, Espeland M, Shumaker S, Henderson V, Brunner R, Manson J . Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289(20):2663-72. DOI: 10.1001/jama.289.20.2663. View

11.

Luo Y, Smith J, Paramasivam V, Burdick A, Curry K, Buford J . Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002; 99(19):12197-202. PMC: 129421. DOI: 10.1073/pnas.182425199. View

12.

Saxton J, Ratcliff G, Munro C, Coffey E, Becker J, Fried L . Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol. 2001; 14(4):526-34. DOI: 10.1076/clin.14.4.526.7204. View

13.

Pietri S, Maurelli E, Drieu K, Culcasi M . Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol. 1997; 29(2):733-42. DOI: 10.1006/jmcc.1996.0316. View

14.

Bernick C, Katz R, Smith N, Rapp S, Bhadelia R, Carlson M . Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005; 65(9):1388-94. DOI: 10.1212/01.wnl.0000182897.18229.ec. View

15.

Snitz B, Saxton J, Lopez O, Ives D, Dunn L, Rapp S . Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study. Aging Ment Health. 2009; 13(2):171-82. PMC: 2767255. DOI: 10.1080/13607860802380656. View

16.

Hindmarch I . [Activity of Ginkgo biloba extract on short-term memory]. Presse Med. 1986; 15(31):1592-4. View

17.

Allain H, Raoul P, Lieury A, Lecoz F, Gandon J, DArbigny P . Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther. 1993; 15(3):549-58. View

18.

Hughes C, Berg L, Danziger W, COBEN L, Martin R . A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140:566-72. DOI: 10.1192/bjp.140.6.566. View

19.

Solomon P, Adams F, Silver A, Zimmer J, DeVeaux R . Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002; 288(7):835-40. DOI: 10.1001/jama.288.7.835. View

20.

Kaschel R . Ginkgo biloba: specificity of neuropsychological improvement--a selective review in search of differential effects. Hum Psychopharmacol. 2009; 24(5):345-70. DOI: 10.1002/hup.1037. View